Volume 3, Issue 2
Research Articlep. 255
Preoperative manometry is not a predictor of postoperative dysphagia in chagasic achalasia
Author(s): Fernando Augusto Mardiros Herbella, Nelson Eduardo Acebey, Edson T Yanagita and Jose Carlos Del Grande
Appendicesp. 328
Acknowledgement: Volume 3 Issue 2
Appendicesp. 324
Appendices: Volume 3 Issue 2
Appendicesp. 322
Glossary: Volume 3 Issue 2
Short Reportp. 299
Acacia gum therapeutic potential: possible role in the management of uremiaAA a new potential medicine
Author(s): Aamir Jalal Al-Mosawi
Review Articlep. 273
Rehabilitation of the younger adult stroke patient
Author(s): P Makela, U Hammerbeck and DN Rushton
Research Articlep. 265
Continuous renal replacement in the developing world: is there any alternative?
Author(s): Aamir Jalal Al Mosawi
Research Articlep. 259
Population pharmacokinetic analysis of the microemulsion formulation of cyclosporin A (Neoral�®) in renal transplant patients
Author(s): Dawei Xuan, Charles H Nightingale, David Hull and David P Nicolau
Editorialp. 183
Acacia gum in chronic renal failure
Author(s): Russell W Chesney and Andrea B Patters
Research Articlep. 251
Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study
Author(s): Angelo Zullo, Vincenzo De Francesco, Cesare Hassan, Carmine Panella, Sergio Morini and Enzo Ierardi
Review Articlep. 247
Roflumilast for the treatment of chronic obstructive pulmonary disorder SA Antoniu
Author(s): Sabina A Antoniu
Drug Evaluationp. 237
Tamsulosin modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia
Author(s): Marleen M van Dijk, Jean JMCH de la Rosette and Martin C Michel
Drug Evaluationp. 227
Esomeprazole: a new proton-pump inhibitor for NSAID-associated peptic ulcers and dyspepsia
Author(s): Grace Lai-Hung Wong and Joseph JY Sung
Drug Evaluationp. 201
Enteric-coated mycophenolate mofetil: role in transplantation
Author(s): Maurizio Salvadori and Elisabetta Bertoni
Drug Evaluationp. 191
Infliximab: a chimeric anti-TNF-A monoclonal antibody for the treatment of ankylosing spondylitis and other spondyloarthritides
Author(s): Dominique Baeten
Bulletin Boardp. 5
